Custom crystal celebrating FDA acceptance of the Investigational Drug Application for XTX101, a potential treatment for cancer patients.
(21AJH115)
The Corporate Presence can provide a range of commemorative designs, including those for FDA approvals, treatment studies, licensing, development, and commercialization agreements, and drug launches. We have unmatched expertise and experience in embedding drug vials.
Custom crystal celebrating FDA acceptance of the Investigational Drug Application for XTX101, a potential treatment for cancer patients.
(21AJH115)Crystal commemorative recognizing a collaboration involving Virginia Commonwealth University’s Medicine for All Institute.
(20AJH069)Custom Lucite, with an embedded drug vial, celebrating FDA approval of Cosela. (20ADH005)
Crystal commemorative recognizing team members in a first in-human clinical study of an anti-tumor therapy.
(9AJH024)Lucite commemorative, incorporating a drug vial, celebrating the first product shipment by generic pharmaceutical company Civica.
(9AKL475)Custom Lucite commemorating seed financing for Martin Pharmaceuticals. The design replicates the packaging for LIVANTRA, an orphan drug for the treatment of Acute-on-Chronic Liver Failure (ACLF). (8AMF069)
Crystal commemorative celebrating a development and commercialization agreement between Click Therapeutics and pharmaceutical firm Boehringer Ingelheim. The partnership centers on a mobile prescription app providing digital treatment for patients with schizophrenia.
(21AKL599)Lucite embedment with drug vial commemorating a study of a treatment for solid tumor cancer.
(21ADH006)Custom crystal commemorative celebrating the launch of Wynzora Cream, a topical treatment for plaque psoriasis that received approval from the FDA (Food and Drug Administration) in 2020. The product launch resulted from a collaboration agreement between Denmark-based MC2 Therapeutics, and EPI Health, a specialty pharmaceutical firm headquartered in Charleston, South Carolina.
(21ADH022)
